CBLI Breaking News

Posted: September 24, 2011 at 9:31 am

This post was added by Dr. Richardson


Video Download: YouTube Video Here


CBLB502 was granted Fast Track and Orphan Drug designations from the FDA for reducing the risk of or preventing death following total body irradiation during or after radiation disaster. The FDA Fast Track program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs. Such programs include expanded communications (both verbal and written), rolling BLA submission and reviews, priority review (6 month action date instead of 10 month action date) and accelerated drug approval (approval on the basis of a surrogate endpoint).

View post:
CBLI Breaking News

Related Post
This entry was posted in FDA Stem Cell Trials. Bookmark the permalink.

Comments are closed.